Results 231 to 240 of about 236,432 (265)

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, EarlyView.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

A novel bispecific antibody targeting OX40L and TNFα for the targeted treatment of rheumatoid arthritis. [PDF]

Antib Ther
Zhang Q, Song S.
europepmc   +1 more source

Enhancing antitumour response to proteasome inhibitors with inhibitors of insulin‐degrading enzyme, a new molecular vulnerability in multiple myeloma

British Journal of Pharmacology, EarlyView.
Inhibitors of insulin‐degrading enzyme boost PI cytotoxicity through an increased sensitivity of proteasome to PI inhibitors, induction of ISR, DNA damage and Myc down‐regulation. They overcome PI resistance in vitro and induce tumour regression in vivo.
Laetitia Lesire, Rebecca Deprez‐Poulain, Damien Bosc, Florence Leroux, Valerie Landry, Sarah Ourabah, Morgane Tardy, Clara Maillard, Ronan Gealageas, Julie Dumont, Adrien Herledan, Sandrine Warenghem, Manon Cruette, Celine Lenglart, Alexandre Biela, Catherine Piveteau, Eva De Smedt, Catharina Muylaert, Wenguang Liang, Elvira Garcia De Paco, Elina Alaterre, Sara Ovejero, Nicolas Robert, Fabien Delahaye, Wei‐Jen Tang, Peter van Endert, Elke De Bruyne, Jérôme Moreaux, Benoit Deprez   +28 more
wiley   +1 more source

Immune-Centered Cross-Talk Between Cancer Cells and the Tumor Microenvironment-Implications for Therapy. [PDF]

Cancers (Basel)
Turlej E, Domaradzka A, Koksharov R, Gizak A.   +3 more
europepmc   +1 more source

Cancer pain: current practice and emerging targets

British Journal of Pharmacology, EarlyView.
Cancer pain (CP) arises from a complex interplay between the tumour and its microenvironment. Many patients experience a mixed pain phenotype that encompasses nociceptive, neuropathic and neuroinflammatory mechanisms, and vary across tumour type and disease stage. Despite decades of intensive research, the mainstay of cancer pain treatment is still non‐
Yi Ye, Marcin Chwistek, Zhiting Gong, Vanessa Uzonwanne, Xiaojie Shi, Arpad Szallasi   +5 more
wiley   +1 more source

Immunomodulatory biomaterials for treating chronic inflammation at mucosal sites. [PDF]

NPJ Biomed Innov
Babb LM, Kulapurathazhe MJ, Collier JH.
europepmc   +1 more source

A Monoclonal Antibody ELISA-Based Assay for Measuring the Potency of Candidate H5 Clade 2.3.4.4b Pandemic Influenza Vaccines. [PDF]

Influenza Other Respir Viruses
Odin M, Schmeisser F, Soto J, Weir JP.
europepmc   +1 more source

Rapidly acquired HIV-1 neutralization breadth in a rhesus V2 apex knockin mouse model after a single bolus immunization. [PDF]

Sci Immunol
Ghosh AR, Habib R, Mishra N, Roark RS, Akauliya M, Albowaidey AA, Allen JD, Amereh K, Avillion G, Bottermann M, Liang B, Chaudhary N, Callaghan S, Dye J, Li X, Ellis-Pugh JR, Roy Chowdhury R, James NE, Liu X, Maiorino L, Villavicencio PM, Nedellec R, Oberoi P, Sowers KJ, Park Y, Prum T, Rodriguez L, Ssozi M, Torres JL, Walsh AA, Warner JE, Weldon SR, Xu L, Wiehe K, Crispin M, Ward AB, Nair U, Hahn BH, Burton DR, Shapiro L, Kwong PD, Irvine DJ, Andrabi R, Shaw GM, Batista FD.   +44 more
europepmc   +1 more source

Nintedanib enhances the antitumor efficacy of pd-1 blockade, potentially through inhibition of myeloid-derived suppressor cells and cancer-associated fibroblasts. [PDF]

Cancer Immunol Immunother
Suzuki R, Watanabe S, Shono K, Masuda T, Yanai K, Yamazaki R, Ando Y, Wakabayashi T, Tanaka S, Sekiya T, Kushiro K, Yanagimura N, Sato M, Tanaka T, Nozaki K, Saida Y, Hokari S, Arita M, Ohashi R, Shima K, Kimura Y, Aoki N, Ohshima Y, Koya T, Kikuchi T.   +24 more
europepmc   +1 more source

A humanized LIF-targeting antibody synergistically enhances chemo- and immunotherapy in pancreatic cancer. [PDF]

J Transl Med
Xu F, Liu W, Su L, Yang L, Zhang Y, Liu B, Liu S, Liu Z, Chen Z, Lu Y, Zhang N, Huang R, Zhao H, Song W.   +13 more
europepmc   +1 more source